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sample t-test to evaluate glycemic control associated with CANA. RESULTS: A total 
of 9,805 CANA users were identified, among which 6,571 (67%) were in the CANA100 
group (mean age: 59; 48% female; 75% white; mean Charlson Comorbidity Index 
[CCI]: 1.8; mean Diabetes Complications Severity Index [DCSI]: 0.9) and 3,234 (33%) 
were in the CANA300 group (mean age: 57; 44% female; 75% white; mean CCI: 1.6; 
mean DCSI: 0.8). Before the index date, 98% and 97% of patients were prescribed 
≥ 1 antihyperglycemic agent, with a mean number of 5.6 and 5.5 antihyperglyce-
mic agents per patient in the CANA100 and CANA300 groups, respectively. In the 
6 months following CANA initiation, mean HbA1c values decreased from 8.4% to 
7.9% (p< 0.0001) among CANA100 patients and from 8.5% to 7.8% (p< 0.0001) among 
CANA300 patients. CONCLUSIONS: Patients treated with CANA in the real-world 
setting often received multiple prior diabetes treatments and had uncontrolled 
HbA1c levels. Patients taking CANA significantly improved their HbA1c values, with 
numerically greater improvement in those with CANA 300mg.
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OBJECTIVES: Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor recently 
approved for T2DM treatment, which does not require dose adjustment in 
patients with renal or hepatic impairment. The patterns of treatment adher-
ence among patients initiating linagliptin in routine care settings are largely 
unknown. METHODS: Within a large, nationwide US health insurance database 
(Optum Clinformatics), we identified T2DM patients ≥ 18 years initiating linagliptin 
or other NIDMs from May 2011 through June 2012. Patients were followed for adher-
ence measures for up to 12 months. Findings were replicated in a propensity score 
(PS)-matched population and in another US commercial health insurance database 
(MarketScan). RESULTS: Of 155,345 T2DM patients initiating a NIDM, 46.8% initiated 
metformin, followed by sulfonylureas (21.8%), and sitagliptin (11.9%). Linagliptin was 
initiated by 2,820 patients (1.8%). Linagliptin and saxagliptin initiators had the high-
est proportion of days covered [PDC] (77.5% and 75.8%, respectively) and medication 
possession ratio [MPR] (0.67 and 0.66). Similarly, compared to initiators of other 
agents, these patients less frequently filled only one dispensing of their medica-
tion [1DISP] (15.0% for linagliptin and 15.7% for saxagliptin), and more persisted on 
therapy at 12 months [P12] (51.5% and 49.8%). Metformin initiators had PDC = 70.4%, 
MPR = 0.57, 1DISP = 23.0%, and P12 = 35.5%. The lowest adherence measures were 
observed among initiators of meglitinides (PDC 64.0%; MPR 0.46; 1DISP 32.4%; P12 
22.6%), glitazones (PDC 68.8%; MPR 0.51; 1DISP 30.2%; P12 28.4%) and GLP-1 receptor 
agonists (PDC 68.3%; MPR 0.54; 1DISP 23.3%; P12 33.6%). These patterns of adherence 
were similar after PS-matching and in MarketScan data, suggesting differences in 
adherence were not due to patient or health insurer characteristics. CONCLUSIONS: 
Compared to other NIDMs, patients initiating linagliptin (along with saxagliptin) 
exhibit greater adherence to therapy. The observed patterns of adherence are not 
likely to be due to patient or health insurer characteristics.
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OBJECTIVES: Chronic activation of the pathological arm of the renin angiotensin 
system (RAS) contributes to lung fibrosis, chronic inflammation, impaired immune 
function and oxidative stress in type 2 diabetic (T2D) patients. Studies have shown 
that diabetic patients treated with angiotensin-converting-enzyme (ACE) inhibitors 
or angiotensin II receptor blockers (ARBs) achieve a reduction in all-cause mortal-
ity. Our objective is to determine if RAS-modifying medications have a beneficial 
impact on lung health and immunity in T2D patients. METHODS: A retrospec-
tive analysis was conducted using claims data from a US commercial insurance 
company. The study groups consisted of T2D patients taking either: ACE inhibi-
tors, ARBs, control [diuretics or calcium-channel blockers (CCBs)], or combination 
drugs (ACE inhibitors/diuretics, ARBs/diuretics, ACE inhibitors/CCBs, ARBs/CCBs). 
Logistic regression analyses were performed to estimate the association between 
exposure to each treatment and the incidence of respiratory complications: pneu-
monia and influenza (PNIN) or chronic obstructive pulmonary disease and allied 
conditions (COPDAC). RESULTS: A total of 171,857 patients were identified. During 
the 4.5 year of follow-up, patients treated with ACE inhibitors had lower incidence 
of PNIN [8.84%, odds ratio (OR) 0.91, 95% CI 0.86-0.94] or COPDAC (17.1%, OR 0.86, 
95% CI 0.84-0.90), compared to patients treated with control drugs (9.93% and 19.71% 
respectively). ARBs patients also exhibited a lower rate of PNIN (8.89%, OR 0.91, 95% 
CI 0.86-0.97) and COPDAC (17.1%, OR 0.86, 95% CI 0.82-0.90) compared to control. 
Patients treated with combination drugs exhibited the lowest incidence of PNIN 
(8.14%, OR 0.86, 95% CI 0.82-0.91) and COPDAC (16.15%, OR 0.82, 95% CI 0.80-0.86) 
relative to control patients. CONCLUSIONS: Preliminary results suggest that there is 
a measurable benefit from RAS-modifying medications on pulmonary health in T2D 
patients. There are no notable differences in patients treated with either ACE inhibi-
tors or ARBs. Further, there may also be added benefit of using combination therapy.
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FPG levels (MD -2.17 [CI 95% -2.44, 1.91, p< 0.001]) and body weight (MD-2.91 [95% 
CI -3.50, -2.32]) after 26 weeks as compared to placebo. The risk of occurrence of 
urinary tract infections (RR 1.25 [95% CI 0.80, 1.94]), genital mycotic infections 
among males (RR 8.73 [CI 95% 2.07, 36.72, p= 0.003]) and females (RR 4.37 [CI 95% 
2.03, 9.38, p= 0.0002]) was higher in the canagliflozin arm as compared to placebo 
arm. CONCLUSIONS: Canagliflozin significantly decreases HbA1c, FPG levels 
and body weight while increasing the risk of urinary tract infections and genital 
mycotic infections as compared to placebo among patients with inadequately 
controlled T2DM.
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OBJECTIVES: To examine the relationship between different anti-diabetic thera-
pies (DPP-4, metformin and sulfonylureas) and risk of acute pancreatitis among 
type 2 diabetic patients in Taiwan, and explore each drug’s dose-response relation-
ship. METHODS: We derived a nationwide retrospective cohort of patients with 
type 2 diabetes in Taiwan. The inclusion criteria are adult diabetic patients with 
continuous baseline enrollment, new users of the studied drugs, and without miss-
ing demographics. There were 4,113/101,498/44,772 DPP-4/Metformin/Sulfonylurea 
users. Adjusted hazards ratios for pancreatitis associated with DPP-4, derived from 
Cox Proportional Hazard models with propensity score weighting, were estimated; 
dose-response analyses were also conducted. RESULTS: DPP-4 was statistically 
significantly associated with a decreased risk of acute pancreatitis compared to 
sulfonylureas (adjusted HR: 0.36, 95% CI: 0.17-0.75) but not metformin (adjusted HR: 
0.67, 95% CI: 0.32-1.41); metformin was statistically significantly associated with a 
lower risk of pancreatitis than sulfonylurea (adjusted HR: 0. 53; 95% CI, 0.37-0.76). 
In addition, low-dose metformin was statistically significantly associated with a 
lower risk of pancreatitis compared to high-dose metformin (HR: 0.65; 95% CI, 0.44-
0.97). CONCLUSIONS: Our findings suggest that sulfonylureas may potentially be 
associated with an increased risk of pancreatitis compared to DPP-4 or metformin. 
This population-based cohort study extends the previous evidence in an ethnic 
Chinese type 2 diabetic cohort. Studies with longer follow up, larger sample sizes 
and more precise capture of confounders may be needed to determine the risk of 
pancreatitis associated with Incretin based therapies.
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OBJECTIVES: Real-world evidence on adherence to glucagon-like peptide-1 recep-
tor agonist (GLP-1RA) in elderly or disabled patients is limited. Patient adherence to 
an antidiabetic regimen is a clinical challenge when considering the medical com-
plexities of T2DM in elderly patients and other comorbidities associated with aging. 
GLP-1RA therapies such as exenatide once weekly (QW) and liraglutide once daily 
(QD) are an increasingly used class of drugs with proven efficacy and tolerability. 
The current study examined adherence to medication in patients age ≥ 65 years 
with T2DM initiating a GLP-1RA. METHODS: The study used medical and pharmacy 
claims between 2010 and 2013 for Medicare members in a US health plan diagnosed 
with T2DM and were new initiators of either exenatide QW (n= 537) or liraglutide QD 
(n= 3673) during that time frame and were continuously enrolled for 6 months pre- 
and post-index. Proportion of Days Covered (PDC) ≥ 80% was used to determine post-
index adherence. Logistic regression models controlled for baseline demographics, 
comorbidities and T2DM treatments. RESULTS: A significantly higher percentage of 
patients on exenatide QW had a PDC ≥ 80% (43.2%) vs liraglutide QD (35.0%, χ 2, p< .01). 
Adjusted results indicated patients on liraglutide QD were 20.1% (p< .01) less likely to 
be adherent than patients on exenatide QW. Two other significant factors associated 
with lower adherence were: evidence for cardiovascular disease and plan type. The 
mean proportion of days covered showed patients on exenatide QW had a slightly 
higher medication possession rate of GLP1-RA compared with patients on liraglutide 
QD: 63.5% vs. 61.5% (ns). CONCLUSIONS: Results from this retrospective study sug-
gest that overall adherence to GLP-1RAs was low, but was better with exenatide QW. 
Patients 65 years and older treated with exenatide QW had a significantly higher 
adherence rate compared to liraglutide QD. Further research is needed to validate 
these findings in other patient populations.
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OBJECTIVES: Canagliflozin (CANA), an agent that inhibits sodium glucose co-
transporter 2, has been shown to improve glycemic control in patients with T2DM 
in clinical trials. The current study described the early clinical characteristics and 
glycemic control of T2DM patients receiving different doses of CANA following 
approval of CANA in a real-world setting. METHODS: Adults with ≥ 1 diagnosis for 
T2DM and ≥ 6 months of clinical activity before first CANA prescription (index) were 
identified in the Cegedim Strategic Data US electronic medical records database, in 
which 60% of contributors are primary care providers. Patients were stratified by 
their first CANA daily dose (100mg [CANA100] or 300mg [CANA300]) observed in the 
database. Patients’ clinical characteristics were assessed descriptively and HbA1c 
levels at baseline and 6 months after the index date were compared using paired 
